Once I have a chance to re-listen to the cc, I'll post an update to the XOMA RMF however here's my initial take-away:
1) For the first time, the company discussed the results of the Servier Ph2 follow-on trial in Behçet's. Of 21 pts enrolled, 17 were considered acute and 4 were "at risk." 11 pts had a vitreous haze score at enrollment that was greater than or equal to 2+ which is also the enrollment threshold in the Eyeguard A Ph3 trial. 8 of 11 patients (72%) experienced a 2 unit reduction. For reference, Eyeguard A is powered to show a 40% response. The primary endpoint for Eyeguard A is the proportion of patients to see 2 unit improvement in their vitreous haze score day 56.
2) The company announced a parallel PoC trial in erosive osteoarthritis (EOA) of the hand in patients who do not meet the "active inflammatory" enrollment threshold. If Gevokizumab proves active in this broader patient population, the market opportunity in EOA could expand from 500k to 1.8M.
Market Data 
Markets 
AI
